Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.14738 http://scihub22266oqcxt.onion/10.1111/ajt.14738 C6055813!6055813!29573335     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2018 ; 18 (7): 1774-82 Nephropedia Template TP {{tp|p=29573335|t=2018. Posttransplant reduction in preexisting donor?specific antibody levels after belatacept? versus cyclosporine?based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT?EXT |pdf=|usr=}}{{29573335}} gab.com Text Posttransplant reduction in preexisting donor specific antibody levels after belatacept versus cyclosporine based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT EXT JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=29573335 #FOAvip BENEFIT and BENEFIT?EXT were phase III studies of cytotoxic T?cell crossmatch?negative kidney transplant recipients randomized to belatacept more intense (MI)?based, belatacept less intense (LI)?based, or cyclosporine?based immunosuppression. Following study completion, presence/absence of HLA?specific antibodies was determined centrally via solid?phase flow cytometry screening. Stored sera from anti?HLA?positive patients were further tested with a single?antigen bead assay to determine antibody specificities, presence/absence of donor?specific antibodies (DSAs), and mean fluorescent intensity (MFI) of any DSAs present. The effect of belatacept?based and cyclosporine?based immunosuppression on MFI was explored post hoc in patients with preexisting DSAs enrolled to BENEFIT and BENEFIT?EXT. In BENEFIT, preexisting DSAs were detected in 4.6%, 4.9%, and 6.3% of belatacept MI?treated, belatacept LI?treated, and cyclosporine?treated patients, respectively. The corresponding values in BENEFIT?EXT were 6.0%, 5.7%, and 9.2%. In both studies, most preexisting DSAs were of class I specificity. Over the first 24 months posttransplant, a greater proportion of preexisting DSAs in belatacept?treated versus cyclosporine?treated patients exhibited decreases or no change in MFI. MFI decline was more apparent with belatacept MI?based versus belatacept LI?based immunosuppression in both studies and more pronounced in BENEFIT?EXT versus BENEFIT. Although derived post hoc, these data suggest that belatacept?based immunosuppression decreases preexisting DSAs more effectively than cyclosporine?based immunosuppression. Twit Text FOAVip Posttransplant reduction in preexisting donor specific antibody levels after belatacept versus cyclosporine based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT EXT ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=29573335 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29573335 #FOAvip English Wikipedia <ref>{{Cite pmid|29573335}}</ref> Posttransplant reduction in preexisting donor?specific antibody levels after belatacept? versus cyclosporine?based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT?EXT #MMPMID29573335 Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier?Kriesche H; Larsen CP Am J Transplant 2018[Jul]; 18 (7): 1774-82 PMID29573335show ga BENEFIT and BENEFIT?EXT were phase III studies of cytotoxic T?cell crossmatch?negative kidney transplant recipients randomized to belatacept more intense (MI)?based, belatacept less intense (LI)?based, or cyclosporine?based immunosuppression. Following study completion, presence/absence of HLA?specific antibodies was determined centrally via solid?phase flow cytometry screening. Stored sera from anti?HLA?positive patients were further tested with a single?antigen bead assay to determine antibody specificities, presence/absence of donor?specific antibodies (DSAs), and mean fluorescent intensity (MFI) of any DSAs present. The effect of belatacept?based and cyclosporine?based immunosuppression on MFI was explored post hoc in patients with preexisting DSAs enrolled to BENEFIT and BENEFIT?EXT. In BENEFIT, preexisting DSAs were detected in 4.6%, 4.9%, and 6.3% of belatacept MI?treated, belatacept LI?treated, and cyclosporine?treated patients, respectively. The corresponding values in BENEFIT?EXT were 6.0%, 5.7%, and 9.2%. In both studies, most preexisting DSAs were of class I specificity. Over the first 24 months posttransplant, a greater proportion of preexisting DSAs in belatacept?treated versus cyclosporine?treated patients exhibited decreases or no change in MFI. MFI decline was more apparent with belatacept MI?based versus belatacept LI?based immunosuppression in both studies and more pronounced in BENEFIT?EXT versus BENEFIT. Although derived post hoc, these data suggest that belatacept?based immunosuppression decreases preexisting DSAs more effectively than cyclosporine?based immunosuppression. äPosttransplant reduction in preexisting donor?specific antibody levels(epmc).pdf DeepDyve Pubget Overpricing